Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 65195208

Next Previous
Search
Drug Profile

JNJ 65195208

Alternative Names: JNJ-65195208 - Janssen; MVA-BN HPV; MVA.HPV16/18 - Janssen

Latest Information Update: 24 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Janssen
  • Class Antivirals; Papillomavirus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Human papillomavirus infections

Most Recent Events

  • 24 Nov 2021 Discontinued - Phase-I/II for Human papillomavirus infections in Belgium, USA (IM) (Bavarian Nordic pipeline, November 2021)
  • 15 Oct 2020 Janssen Vaccines & Prevention terminates phase I/II trial in Human papillomavirus infections in Belgium and USA due to low enrolment and increasing COVID restrictions (IM) (NCT03610581)
  • 09 Nov 2018 Janseen plans a phase I/IIa trial in Human papillomavirus infections in the second half of 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top